Comparative study between the efficacy of prabotulinum toxin‐A versus onabotulinum toxin‐A for the treatment of upper facial expression lines

Abstract

AbstractBackgroundBotulinum Toxin (BoNTA) is the most used nonsurgical aesthetic procedure to treat facial expression lines.AimsThis study compared the efficacy of Prabotulinum toxin‐A, a novel BoNTA that originates from Clostridium botulinum Hall‐A, with onabotulinum toxin‐A in treating facial expression lines using the Facial Wrinkle Scale (FWS) and FACE‐Q questionnaires.MethodsThis was an experimental, comparative, longitudinal, open‐label, and prospective study. Patients aged between 25 and 40 years with upper‐third facial expression lines were included. Follow‐ups were made at three, seven, 30, and 120 days.ResultsA total of 26 patients were included: 20 female, and six males, with a mean age of 28.26 years. An average of 31.00 IU and 31.38 IU were administered to the onabotulinum and prabotulinum groups, respectively. The prabotulinum group demonstrated superiority in FWS and Face‐Q scores between the first and third days (p ≤ 0.001, p < 0.001, respectively), which continued on day 7. By day 30, there were no differences in the scores of the two questionnaires.ConclusionsPrabotulinum toxin‐A is a safe and effective treatment for upper‐third facial wrinkles. On day three and seven, the results suggest that prabotulinum toxin‐A has a quicker onset of action than onabotulinum toxin‐A. On days 30 and 120, both groups showed similar FWS and Face‐Q scores.